Zoetis Launches Simparica Trio Once-monthly Combination Canine Antiparasitic In Europe
Zoetis, the world’s leading animal health company, today announced the European launch of Simparica TrioTM – a once-monthly triple combination (sarolaner/moxidectin/pyrantel) antiparasitic medication for dogs with, or at risk from, mixed external and internal parasitic infestations.
“With Simparica Trio, we bring to market an advanced parasiticide solution, helping to deliver improved client satisfaction and patient protection,” said Rob Kelly, President, International Operations at Zoetis. “Thanks to its broad spectrum, Simparica Trio helps veterinarians and dog owners provide more complete parasite coverage with a single-monthly chewable tablet. The broad spectrum of Simparica Trio minimizes the potential risk of parasite protection gaps.”
The innovative, chewable, prescription-only tablet contains sarolaner, which kills fleas and ticks; moxidectin, effective in the prevention of heartworm, lungworm disease, and for the treatment of some intestinal worms; and pyrantel embonate, effective against gastrointestinal nematodes (hookworms and roundworms).
Dr. Domenico Otranto, DVM, PhD, DipEVPC, Professor in Veterinary Parasitology at the University of Bari in Italy, who presented at the launch, said: “Simparica Trio has been shown to rapidly kill fleas and ticks in association with its efficacy for the prevention of heartworm disease and angiostrongylosis (lungworm disease). It also treats intestinal roundworms and hookworms. Therefore, the new oral chewable provides veterinarians with a safe and effective option for treating external and internal parasitic infestations in dogs. The once-monthly format and chewable formulation help increase compliance with treatment, giving veterinarians and dog owners confidence in continuous protection.”
Professor Tim Geary, BSc PhD, Professor Emeritus, Institute of Parasitology, McGill University, Canada, and Professor, School of Biological Sciences, Queen’s University – Belfast, NI, highlighted the importance of choosing the right protection from clinically important parasites: “Serious diseases that are preventable and of increasing prevalence threaten dogs in Canada and Europe. Simparica Trio today offers a better solution to preventing and controlling these parasites against the concern of their increasing prevalence.”
Efficient Treatment for the Most Common Internal and External Parasites in Dogs
Simparica Trio was shown to provide immediate and persistent killing activity for up to five weeks against two species of fleas (Ctenocephalides felis and C. canis) and for up to five weeks for the most common ticks in the EU (Ixodes hexagonus, Ixodes ricinus, Rhipicephalus sanguineus) or up to four weeks for (Dermacentor reticulatus). It demonstrated a rapid onset of action, killing fleas before they could lay eggs, and can be used as part of a treatment strategy for the control of flea allergy dermatitis. In addition, Simparica Trio is indicated for the prevention of heartworm disease (Dirofilaria immitis) and lungworm disease (Angiostrongylus vasorum) and the treatment of gastrointestinal roundworm and hookworm infections of Toxocara canis (immature adults (L5) and adults); Ancylostoma caninum (L4 larvae, immature adults (L5) and adults); Toxascaris leonina (adults); and Uncinaria stenocephala (adults). Simparica Trio’s spectrum includes immature A. caninum and T. canis, which are important in controlling environmental contamination and minimizing human exposure to these zoonotic parasites.
The marketing authorization for Simparica Trio in Europe was based on the results of veterinary patient studies conducted in eight countries, involving more than 1,900 dogs of various breeds. The product is indicated for dogs from at least eight weeks of age and 1.25 kg of bodyweight.
Simparica Trio chewable tablets will be available in six tablet strengths for dogs of all sizes.
For more information about Simparica Trio and full prescribing information, visit https://www.zoetis.com.
 Dr Otranto has a consulting relationship with Zoetis
 Professor Tim Geary has a consulting relationship with Zoetis
More from Zoetis
- Zoetis Launches the First Oral Vaccine for Dogs in Europe
- HorseDialog Sponsors Current Eventing World Champion Ros Canter
- Survey Results Show Desire to Improve Awareness of Equine Herpes Virus (EHV)
- Zoetis Supports Veterinary Extramural Studies With Recognition Awards
- Zoetis receives European Commission Approval for Variation Group on Suvaxyn PRRS MLV Vaccine